Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Larimar Therapeutics, Inc.

https://larimartx.com/

Latest From Larimar Therapeutics, Inc.

Larimar Secures PRIME Designation In EU For Neurological Disease Drug

The European Medicines Agency has accepted Larimar’s potential treatment for Friedreich’s ataxia onto its PRIME scheme for helping to get medicines for unmet medical needs to patients faster.

Europe Research & Development

Clinical Hold Halts Larimar’s Friedrich’s Ataxia Candidate And Financing

Looking to develop the first drug therapy for FA, Larimar gets US FDA hold due to deaths in non-human primate study. This alters clinical development timelines and fundraising plans for the firm.

Clinical Trials Drug Safety

Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Clinical Trials Coronavirus COVID-19

Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics

Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Chondrial Therapeutics, Inc.
    • Zafgen, Inc.
UsernamePublicRestriction

Register